During the last decades, a better understanding of the biology of multiple myeloma (MM) has led to the application of novel treatment strategies for MM patients. The new anti-myeloma regimens produce higher incidence of durable and of better quality responses and they improve overall survival, challenging the dogma of incurable disease, outside the context of allogeneic transplantation. This review presents all these strategies that aim to cure MM, including continuous treatment i.e. induction, consolidation and maintenance, treatment of asymptomatic MM and monitoring minimal residual disease using modern techniques, such as multi-parameter flow cytometry, molecular assays and advanced imaging.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.transci.2016.01.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advancements in the Treatment of Multiple Myeloma.
Cureus
December 2024
Hematology, Hospital Clínica Bíblica, San José, CRI.
Article Synopsis
- Multiple myeloma (MM) is the second most prevalent blood cancer worldwide, traditionally viewed as aggressive and deadly.
- Recent advancements in treatment, such as proteasome inhibitors, monoclonal antibodies, immunomodulators, and corticosteroids, have improved patient outcomes significantly.
- Due to innovative combination therapies and ongoing research, there is growing optimism for future treatments, aiming to make MM more manageable and potentially curable.
Surgical management of cervical malignant spinal lesions: a retrospective study of cervical spine metastases and multiple myeloma cases.
Acta Neurochir (Wien)
December 2024
Department of Spine Surgery, Zentralklinik Bad Berka, Bad Berka, Germany.
Purpose: This study introduces a retrospective analysis of the surgical management of 213 consecutive cases of cervical spine metastases and Multiple Myeloma Cases.
Materials And Methods: Retrospective analysis of prospectively collected data in a single surgical center of patients who underwent surgery for tumors of the cervical spine between 1994 and 2017. Exclusion criteria were intradural tumors and primary tumors.
Minimal residual disease in multiple myeloma.
Presse Med
December 2024
Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France. Electronic address:
Minimal Residual Disease (MRD) in multiple myeloma has emerged as a significant prognostic factor, guiding treatment strategies and enhancing patient outcomes. Despite advancements in therapies such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, CAR-T cell therapy, and bispecific antibodies, complete eradication of malignant plasma cells remains challenging. MRD refers to a small number of residual cancer cells that persist after treatment and require sensitive methods like next-generation flow cytometry (NGF) and next-generation sequencing (NGS) for detection.
View Article and Find Full Text PDFSecondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma.
Eur J Haematol
December 2024
Department of Oncology and Haematology, Klinikum Oldenburg, University Clinic, Oldenburg, Germany.
Background: Secondary malignancies are potential complications after high-dose therapy and autologous stem cell transplantation (ASCT). Information on the detailed course of such events is scarce, yet may be essential to minimize the impact of these sequelae.
Patients And Methods: We regularly monitored 877 patients for up to 31 years after ASCT in our outpatient department.
Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma.
J Immunother Cancer
December 2024
Department of Geriatrics, Ruhr University Bochum, University Hospital Marien Hospital Herne, Herne, Germany
The treatment landscape for lymphoma and multiple myeloma, which disproportionally affect older adults, has been transformed by the advent of T cell-mediated immunotherapies, including immune checkpoint inhibition, T cell-engaging bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapy, during the last decade. These treatment modalities re-enable the patient's own immune system to combat malignant cells and offer the potential for sustained remissions and cure for various diseases.Age profoundly affects the physiological function of the immune system.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!